This Phase I study is trying to understand the recommended dose, safety and effective of a new targeted therapy (PSB202) in people with previously treated B-cell cancers.
This trial is treating patients with Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinaemia, and Chronic Lymphocytic Leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Commercial Sponsor
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Summary
This trial has two phases and is trialling a new therapy in patients with indolent-, relapsed-, CD20+ and CD37+ expressing B-cell malignancies. Phase 1a is a 3+3 dose escalation design where participants will receive PSB202 in ascending dose levels. Phase 1b is focusing on dose expansion and follows a Simon's Two-Stage design. Phase 1b enrols up to 20 patients in each of one of three disease-specific cohorts: (1) follicular lymphoma; (2) chronic lymphocytic leukaemia and small lymphocytic lymphoma; (3) a mixed indolent B-cell histology cohort comprising Waldenstrom Macroglobulinemia, indolent phenotype Mantle Cell Lymphoma, and Marginal Zone Lymphoma.
Recruiting Hospitals Read More